From the Canberra Rheumatology; College of Health and Medicine, Australian National University; Clear Vision Consulting; Discipline of Optometry, University of Canberra; Department of Rheumatology, Canberra Hospital, Canberra; Centre for Kidney Research, The Children's Hospital at Westmead; Dragon Claw (Web site for patients with rheumatic disease); Department of Rheumatology, Liverpool Hospital; Ingham Institute of Applied Medical Research; Department of Rheumatology, Royal North Shore Hospital; Institute of Bone and Joint Research, Kolling Institute of Medical Research; Northern Clinical School, and the School of Public Health, The University of Sydney, Sydney; Lord Street Specialist Centre, Port Macquarie; Mayo Hospital Specialist Centre, Taree; Mid-North Coast Arthritis Clinic; University of New South Wales Rural Clinical School, Coffs Harbour, Australia; Department of Medicine, McGill University; Centre for Outcomes Research and Evaluation, McGill University Health Centers, Montreal; Musculoskeletal Health and Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy and the Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland; Medicine Service, VA Medical Center, Birmingham; Department of Medicine, School of Medicine, and the Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama, USA; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health, Amsterdam; University of Twente, Department of Psychology, Health and Technology, Enschede, the Netherlands.
A. Kelly, FRACP, Australian National University, Canberra Rheumatology, and College of Health and Medicine, Australian National University, and Centre for Kidney Research, The Children's Hospital at Westmead; S.J. Bartlett, PhD, Department of Medicine, McGill University, and Centre for Outcomes Research and Evaluation, McGill University Health Centers, and Division of Rheumatology, Johns Hopkins School of Medicine; M.P. de Wit, PhD, Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health, and OMERACT Patient Research Partner; D.E. Beaton, PhD, University of Toronto Musculoskeletal Health and Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, and the Institute of Health Policy Management and Evaluation, University of Toronto; T. Dawson, MPH, Lord Street Specialist Centre, and Mayo Hospital Specialist Centre; V. Evans, PhD, Clear Vision Consulting, and OMERACT Patient Research Partner, and Discipline of Optometry, University of Canberra; M. Gill, BA, Australian National University, and Dragon Claw, and OMERACT Patient Research Partner; G. Hassett, PhD, University of New South Wales, and Department of Rheumatology, Liverpool Hospital, and Ingham Institute of Applied Medical Research; L. March, PhD, Department of Rheumatology, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute of Medical Research, and Northern Clinical School, The University of Sydney; M. Scholte-Voshaar, MSc, Vrije Universiteit Amsterdam, and University of Twente, Department of Psychology, Health and Technology, Enschede, and OMERACT Patient Research Partner; J.A. Singh, MD, Medicine Service, VA Medical Center, and Department of Medicine, School of Medicine, University of Alabama, and Division of Epidemiology, School of Public Health, University of Alabama; A. Tong, PhD, Centre for Kidney Research, The Children's Hospital at Westmead, and University of Sydney, School of Public Health; P. Tugwell, MD, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute; P. Wong, PhD, Mid-North Coast Arthritis Clinic, and University of New South Wales Rural Clinical School; K. Tymms, FRACP, Canberra Rheumatology, and College of Health and Medicine, Australian National University, and Department of Rheumatology, Canberra Hospital.
J Rheumatol. 2019 Sep;46(9):1202-1206. doi: 10.3899/jrheum.181078. Epub 2019 Jan 15.
The OMERACT-Adherence meeting was convened to discuss the conceptual and methodological challenges in developing a core domain set (Adherence-CDS) for trials of interventions for medication adherence in rheumatology.
Forty participants from nine countries participated.
Four ideas emerged: for adherence trials, the Adherence-CDS could include adherence and the condition-specific CDS; many factors affect adherence and are intervention targets, contextual factors, or outcome domains; adherence is a critical factor in drug trials; and standardized adherence measures are needed.
Despite the challenges, the meeting clarified an approach to developing an Adherence-CDS that complements existing OMERACT work and methodology.
召开 OMERACT 一致性会议，讨论制定风湿病药物治疗依从性干预核心评估领域集（Adherence-CDS）所面临的概念和方法学挑战。
来自 9 个国家的 40 名参与者参加了会议。
会议形成了 4 个观点：对于依从性试验，Adherence-CDS 可包括依从性和特定疾病的核心评估领域；许多因素影响依从性，也是干预目标、情境因素或结局领域；依从性是药物试验的关键因素；需要标准化的依从性测量方法。
尽管面临挑战，但会议明确了制定 Adherence-CDS 的方法，该方法补充了现有的 OMERACT 工作和方法学。
